NasdaqGS:APLSBiotechs
A Look At Apellis Pharmaceuticals (APLS) Valuation After The Biogen Acquisition Announcement
Why Apellis Pharmaceuticals (APLS) Is On Investors’ Radar
Apellis Pharmaceuticals (APLS) has drawn fresh attention after being acquired by Biogen, with the company now operating as a subsidiary as of May 14, 2026, while its stock continues to trade independently.
See our latest analysis for Apellis Pharmaceuticals.
At a share price of US$41.03, Apellis has seen a sharp 90 day share price return of 89.08% and a 1 year total shareholder return of 135.13%. However, the 3 year total shareholder...